Publication:

Dysregulation of the angiopoietin–Tie-2 axis in sepsis and ARDS

Loading...
Thumbnail Image

Date

2013

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Taylor & Francis
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Parikh, Samir M. 2013. “Dysregulation of the angiopoietin–Tie-2 axis in sepsis and ARDS.” Virulence 4 (6): 517-524. doi:10.4161/viru.24906. http://dx.doi.org/10.4161/viru.24906.

Abstract

Dynamic changes in microvascular endothelial structure and function are pivotal in the acute inflammatory response, the body’s rapid, coordinated effort to localize, sequester, and eliminate microbial invaders at their portal of entry. To achieve this, the endothelium becomes leaky and inflamed, providing innate immune cells and humoral effector molecules access to the site of infection. During sepsis this locally adaptive response becomes manifest throughout the body, leading to dangerous host consequences. Increased leakiness in the pulmonary circulation contributes to acute respiratory distress syndrome (ARDS), a complication of sepsis associated with 40% mortality. Understanding the molecular governance of vascular leak and inflammation has major diagnostic, prognostic, and potentially therapeutic implications for this common and pernicious disease. This review summarizes results from cell-based experiments, animal models, and observational human studies; together, these studies suggest that an endothelial receptor called Tie2 and its ligands, called angiopoietins, form a signaling axis key to the vascular dyshomeostasis that underlies sepsis.

Description

Research Data

Keywords

angiopoietin-1, angiopoietin-2, Tie-2, Tie-1, VE-PTP, VE-cadherin, permeability, vascular leakage, sepsis, infection, acute respiratory distress syndrome

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories